Dr. Marie Oliver Metzig

Dr. Marie Oliver Metzig
Institute of Pathology, University Medical Center Mainz
Langenbeckstr. 1, 55131 Mainz
Web page

Research Interests

Immunotherapy revolutionized the therapy of cancer, but for the vast majority of patients it is currently not available. Our research team is interested in inflammatory forms of cell death such as necroptosis, and whether their targeted induction may overcome resistance to cancer therapy. We study the molecular networks that regulate dynamic cell death and survival decisions, and decode signals that dying cancer cells pose to the immune system.

Key techniques: Mammalian cell and tissue culture, live-cell microscopy, biochemistry, molecular biology, in vivo tumor xenograft models, histopathology, immunohistochemistry.

Five Most Relevant Publications
  1. Oliver Metzig, M., & Hoffmann, A. (2022). Controlling Cancer Cell Death Types to Optimize Anti-Tumor Immunity. Biomedicines, 2022. 10(5). doi: 10.3390/biomedicines10050974.
  2. Oliver Metzig M., Tang Y., Mitchell S., Taylor B., Foreman R., Wollman R., Hoffmann A., An incoherent feedforward loop interprets NFκB/RelA dynamics to determine TNF-induced necroptosis decisions. Molecular Systems Biology, 2020. 16(12): e9677; doi: 10.15252/msb.20209677.
  3. Oliver Metzig M., Fuchs D., Tagscherer K., Groene H.-J., Schirmacher P., Roth W., Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB. Oncogene, 2016. 35, 3399-3409.
  4. Metzig M., Gdynia G., Roth W., [Mechanisms of cell death. Novel insights and implications for tumor pathology.] Pathologe, 2012. 33 Suppl 2:241-5. doi: 10.1007/s00292-012-1678-5.
  5. Metzig M., Nickles D., Falschlehner C., Lehmann-Koch J., Straub B., Roth, W., Boutros M., An RNAi screen identifies USP2 as a factor required for TNF-alpha-induced NF-kappaB signaling. International Journal of Cancer, 2011. 129(3): p. 607-18.